Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Rating of “Buy” from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has received an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $21.57.

CLBT has been the subject of a number of research analyst reports. Needham & Company LLC raised their target price on Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. Craig Hallum raised their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th.

Institutional Trading of Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP bought a new stake in shares of Cellebrite DI during the third quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after purchasing an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after purchasing an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC lifted its holdings in shares of Cellebrite DI by 1,583.8% during the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at $100,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Trading Up 2.1 %

Shares of NASDAQ CLBT opened at $26.00 on Friday. The firm has a fifty day simple moving average of $21.98 and a two-hundred day simple moving average of $18.63. Cellebrite DI has a 12 month low of $8.91 and a 12 month high of $26.04. The firm has a market capitalization of $5.35 billion, a PE ratio of -16.77, a price-to-earnings-growth ratio of 3.55 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. During the same period in the prior year, the firm earned $0.09 earnings per share. Cellebrite DI’s revenue was up 27.0% on a year-over-year basis. On average, sell-side analysts predict that Cellebrite DI will post 0.32 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.